PBS updates

Ifinwil (Eflornithine)

eflornithine 192 mg tablet, 100 · ORAL · PBS code 14894X

AUTHORITY_REQUIRED

• • First listed on the PBS: 2025-08-01.
• • Repeats: 2.
• • PBS program: HB.

Eligibility criteria for subsidised access

The following is the government's own wording from the PBS Schedule, shown unchanged.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

High-risk neuroblastoma

Continuing treatment

Patient must have previously received PBS-subsidised treatment with this drug for this condition; AND

Patient must not have developed disease recurrence while receiving treatment with this drug for this condition; AND

The treatment must not exceed a total of 27 cycles (based on 4 weeks per cycle) from the first dose of this drug, regardless of whether it was PBS/non-PBS-subsidised; AND

Must be treated in a hospital/cancer centre by either a: (i) paediatric oncologist, (ii) haematologist; or

Must be treated by a medical practitioner under the direct supervision of either a: (i) paediatric oncologist, (ii) haematologist.

At the time of the authority application, the prescriber should request an appropriate quantity and number of repeats based on the patient's Body Surface Area (BSA), according to the dosing schedule in the TGA approved Product Information.

The following maximum quantity units and repeats may be authorised under this restriction (providing 3 months of therapy for each prescription).

Up to a maximum quantity of 100 units and 1 repeat for a BSA 0.25 m² to less than 0.5 m²;

Up to a maximum quantity of 200 units and 1 repeat for a BSA 0.5 m² to less than 0.75 m²;

Up to a maximum quantity of 200 units and 2 repeats for a BSA 0.75 m² to 1.5 m²;

Up to a maximum quantity of 300 units and 2 repeats for a BSA greater than 1.5 m².

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

High-risk neuroblastoma

Transitioning from non-PBS to PBS-subsidised supply - Grandfather arrangements

Patient must have received non-PBS-subsidised treatment with this drug for this PBS indication prior to 1 August 2025; AND

Patient must not have developed disease recurrence while receiving treatment with this drug for this condition; AND

The treatment must not exceed a total of 27 cycles (based on 4 weeks per cycle) from the first dose of this drug, regardless of whether it was PBS/non-PBS-subsidised; AND

Must be treated in a hospital/cancer centre by either a: (i) paediatric oncologist, (ii) haematologist; or

Must be treated by a medical practitioner under the direct supervision of either a: (i) paediatric oncologist, (ii) haematologist.

At the time of the authority application, the prescriber should request an appropriate quantity and number of repeats based on the patient's Body Surface Area (BSA), according to the dosing schedule in the TGA approved Product Information.

The following maximum quantity units and repeats may be authorised under this restriction (providing 3 months of therapy for each prescription).

Up to a maximum quantity of 100 units and 1 repeat for a BSA 0.25 m² to less than 0.5 m²;

Up to a maximum quantity of 200 units and 1 repeat for a BSA 0.5 m² to less than 0.75 m²;

Up to a maximum quantity of 200 units and 2 repeats for a BSA 0.75 m² to 1.5 m²;

Up to a maximum quantity of 300 units and 2 repeats for a BSA greater than 1.5 m².

Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.